SecBot SecBot
8-K ·Filed Apr 13, 2026

IMA

ImageneBio, Inc.
BEARISH
Impact 6/10
Horizonmonths Processed7mo ago SEC0001193125-26-151942
Killer combo: Material agreement + unregistered equity (likely PIPE/convertible)
Actionable Insight ▼ Bearish

The capital raise addresses immediate funding needs but comes at a significant cost of dilution. Investors should monitor how effectively the company deploys these funds in its clinical development programs, particularly in atopic dermatitis and alopecia areata. The pre-funded nature of these warrants means future dilution is already locked in, which could pressure the stock price when these shares enter the market.

DirectionBearish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.05
T+0 close · Apr 13, 2026 · via day close
Latest settled
−2.07%
T+60 · $5.93
Vs SPY
−10.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 13 $6.05entry
  2. T+1 · 7mo ago −5.29%α −6.50% · $5.73
  3. T+5 · 7mo ago −0.83%α −4.12% · $6.00
  4. T+20 · 6mo ago −7.27%α −15.00% · $5.61
  5. T+60 · 4mo ago −2.07%α −10.99% · $5.93
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

ImageneBio is raising $30 million through a private placement of pre-funded warrants, which allows investors to purchase common stock at a nominal exercise price. The company will use the proceeds for late-phase development in atopic dermatitis and expansion into alopecia areata. This constitutes a dilutive capital raise during a period of financial stress.

Key Financial Metrics

Deal Value
$30.0M
Offering Size
$30.0M

Key Facts

  • ImageneBio is raising $30 million through a private placement of pre-funded warrants
  • The warrants are priced at $5.199 per share with a nominal exercise price of $0.001
  • Proceeds will fund late-phase development in atopic dermatitis and expansion into alopecia areata
  • The transaction represents significant dilution to existing shareholders
  • The company is relying on Section 4(a)(2) exemption for this unregistered offering

Financial Impact

The company will receive approximately $30 million in gross proceeds from the sale of pre-funded warrants

cashdilutionequity

Risk Factors

  • Significant shareholder dilution from the issuance of new shares
  • Potential downward pressure on stock price when warrant shares enter the market
  • Execution risk in clinical development programs funded by this capital

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-151942
Document: d143873dex42.htm0001193125-26-151942
Document: d143873dex41.htm0001193125-26-151942
Document: d143873d8k.htm0001193125-26-151942
Document: 0001193125-26-151942-index-headers.html0001193125-26-151942
Document: 0001193125-26-151942-index.html0001193125-26-151942
Document: 0001193125-26-151942.txt0001193125-26-151942

Track record

10 reports on IMA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.50 Now $3.20 −8.57% settles Feb 12
  2. Nov 9, 20267d ago 8-K Neutral 4/10 Entry $3.81 Now $3.20 −16.01% settles Feb 8
  3. Aug 7, 202614w ago EFFECT Bearish 5/10 Entry $5.69 to $4.10 Now $3.20 +43.76% ▲ +27.94% +25.81% vs SPY
  4. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $6.07 to $4.85 Now $3.20 −47.28% ▼ −20.10% −24.48% vs SPY
  5. Apr 30, 202628w ago DEFA14A Neutral 3/10 Entry $5.66 to $5.76 Now $3.20 −43.46% ▲ +1.77% −1.30% vs SPY
  6. Apr 13, 202631w ago 8-K Bearish 6/10 Viewing Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  7. Apr 13, 202631w ago Press Release Bearish 6/10 Entry $6.05 to $5.93 Now $3.20 +47.11% ▲ +2.07% +10.99% vs SPY
  8. Apr 6, 202632w ago EFFECT Neutral 3/10 Entry $4.55 to $5.77 Now $3.20 −29.67% ▲ +26.81% +13.34% vs SPY
  9. Mar 17, 202634w ago Press Release Neutral 3/10 Entry $5.83 to $5.71 Now $3.20 −45.06% ▼ −1.97% −13.50% vs SPY
  10. Mar 10, 202635w ago Press Release Neutral 4/10 Entry $6.07 to $5.45 Now $3.20 −47.28% ▼ −10.21% −21.90% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens in 6h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 13, 2026